A new study led by Ananda Basu, M.D., used novel non-radioactive, stable glucagon tracers for the first time to characterize glucagon metabolism in humans with and without Type 1 diabetes ...

Ananda Basu, M.D. A new study led by Ananda Basu, M.D., used novel non-radioactive, stable glucagon tracers for the first time to characterize glucagon metabolism in humans with and without Type 1 ...

GLP-1RAs (glucagon-like peptide-1 receptor agonists) have consistently demonstrated a protective effect against ischemic stroke. However, whether this benefit also extends to nontraumatic ...

GLP-1RAs (glucagon-like peptide-1 receptor agonists) have consistently demonstrated a protective effect against ischemic stroke. However, whether this benefit also extends to nontraumatic ...

The essential and recommended drugs and equipment required to deal with a medical emergency in a dental practice.

Being cut off in traffic, giving a presentation or missing a meal can all trigger a suite of physiological changes that allows the body to react swiftly to stress or starvation.

Being cut off in traffic, giving a presentation or missing a meal can all trigger a suite of physiological changes that allow the body to react swiftly to stress or starvation. Critical to this "fight ...

Glucagon-like peptide-1 receptor agonists and incidence of obesity-related cancer in adults with diabetes: A target-trial emulation study.. If you have the appropriate software installed, you can ...

Association of glucagon-like peptide 1 receptor agonists with cancer risk in obesity adults with and without diabetes: A target trial emulation study.. If you have the appropriate software installed, ...

Glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) agonists are useful for the treatment of type 2 diabetes and obesity. Controlling GLP-1R signaling parameters, including duration and subcellular ...

The bills would mandate automated defibrillators on campus, require athletes to take an EKG and allow school nurses to administer medicine to a student having a diabetic emergency. Several bills ...

Opko and Entera have formalized their partnership as the biotechs prepare to take the first oral dual agonist GLP-1/glucagon peptide into the clinic.